India establishes inspection guidelines

Share this article:

India's drug regulator is implementing inspection guidelines. The Wall Street Journal reports that the regulator has established an inspection framework that may do away with the haphazard nature of recent inspections.

The FDA has banned imports from four Ranbaxy laboratories after uncovering massive transgressions, and its parent company Sun Pharmaceuticals has also had its share of FDA hand-slaps.

The WSJ notes the FDA has upped its inspections of late, with 111 last year, up from 98 in 2011 and 59 in 2009.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters